COVID-19 Pandemic Leads to Decrease in GI Patient Encounters and New Diagnoses of GI Cancers and Procedures
Investigators analyzed the impact of the COVID-19 pandemic on number of GI procedures performed and new cancer diagnoses.
Investigators analyzed the impact of the COVID-19 pandemic on number of GI procedures performed and new cancer diagnoses.
Study authors compared data of minority patients with COVID-19 to assess whether remdesivir alone or with steroids resulted in clinical improvement.
Study authors conducted a retrospective study to determine the anti-SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized patients with COVID-19.
American Indians/Alaska Natives (AI/ANs) have disproportionate COVID-19 mortality rates.
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
The vaccine candidate is currently in preclinical development with clinical studies expected to begin later this year.
The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.
Patients treated with hydroxychloroquine alone or in combination with azithromycin for pneumonia associated with COVID-19 were found to be at increased risk for corrected QT interval prolongation.
Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.